Long-term safety and efficacy of drug-eluting and bare metal stents in saphenous vein grafts

American Heart Journal

Volumn 164, Issue 1, 2012, Pages 87-93

  Fröbert, Ole ^a   Scherstén, Fredrik ^b   James, Stefan K ^c   Carlsson, Jörg ^d   Lagerqvist, Bo ^c  

^a ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

^d KALMAR COUNTY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; BARE METAL STENT; BLOOD VESSEL; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEATH; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HUMAN; IMPLANTATION; INCIDENCE; LESIONS AND DEFECTS; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPENSITY SCORE; RESTENOSIS; SAPHENOUS VEIN GRAFT; STENT THROMBOSIS; SWEDEN;

AGED; CORONARY ARTERY DISEASE; DRUG-ELUTING STENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; POSTOPERATIVE COMPLICATIONS; SAPHENOUS VEIN; STENTS; TIME FACTORS; VASCULAR SURGICAL PROCEDURES;

EID: 84863637947     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2012.04.012     Document Type: Article

References (29)

1. Fitzgibbon GM, Kafka HP, Leach AJ, et al. Coronary bypass graft fate and patient outcome: angiographic follow-up of 5,065 grafts related to survival and reoperation in 1,388 patients during 25 years. J Am Coll Cardiol 1996;28:616-26. (Pubitemid 26288642)
2. Salomon NW, Page US, Bigelow JC, et al. Reoperative coronary surgery. Comparative analysis of 6591 patients undergoing primary bypass and 508 patients undergoing reoperative coronary artery bypass. J Thorac Cardiovasc Surg 1990;100:250-9.
3. Weintraub WS, Jones EL, Craver JM, et al. In-hospital and long-term outcome after reoperative coronary artery bypass graft surgery. Circulation 1995;92(9 Suppl):II50-7.
4. Weintraub WS, Jones EL, Morris DC, et al. Outcome of reoperative coronary bypass surgery versus coronary angioplasty after previous bypass surgery. Circulation 1997;95:868-77. (Pubitemid 27091527)
5. Savage MP, Douglas Jr JS, Fischman DL, et al. Stent placement compared with balloon angioplasty for obstructed coronary bypass grafts. Saphenous Vein De Novo Trial Investigators. N Engl J Med 1997;337:740-7. (Pubitemid 27417973)
6. Erbel R, Haude M, HoppHW, et al. Coronary-artery stenting compared with balloon angioplasty for restenosis after initial balloon angioplasty. Restenosis Stent Study Group. N Engl J Med 1998;339:1672-8. (Pubitemid 28550692)
7. Morice MC, Serruys PW, Barragan P, et al. Long-term clinical outcomes with sirolimus-eluting coronary stents: five-year results of the RAVEL trial. J Am Coll Cardiol 2007;50:1299-304. (Pubitemid 47454687)
8. Eisenstein EL, Wijns W, Fajadet J, et al. Long-term clinical and economic analysis of the Endeavor drug-eluting stent versus the Driver bare-metal stent: 4-year results from the ENDEAVOR II trial (Randomized Controlled Trial to Evaluate the Safety and Efficacy of the Medtronic AVE ABT-578 Eluting Driver Coronary Stent in De Novo Native Coronary Artery Lesions). JACC Cardiovasc Interv 2009;2:1178-87.
9. Stettler C, Allemann S, Wandel S, et al. Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis. BMJ 2008;337:a1331.
10. Kaltoft A, Kelbaek H, Thuesen L, et al. Long-term outcome after drug-eluting versus bare-metal stent implantation in patients with STsegment elevation myocardial infarction: 3-year follow-up of the randomized DEDICATION (Drug Elution and Distal Protection in Acute Myocardial Infarction) Trial. J AmColl Cardiol 2010;56:641-5.
11. Jeger RV, Schneiter S, Kaiser C, et al. Drug-eluting stents compared with bare metal stents improve late outcome after saphenous vein graft but not after large native vessel interventions. Cardiology 2009;112:49-55.
12. Brilakis ES, Lichtenwalter C, de Lemos JA, et al. A randomized controlled trial of a paclitaxel-eluting stent versus a similar bare-metal stent in saphenous vein graft lesions the SOS (Stenting of Saphenous Vein Grafts) trial. J Am Coll Cardiol 2009;53:919-28.
13. Vermeersch P, Agostoni P, Verheye S, et al. Increased late mortality after sirolimus-eluting stents versus bare-metal stents in diseased saphenous vein grafts: results from the randomized DELAYED RRISC Trial. J Am Coll Cardiol 2007;50:261-7. (Pubitemid 47039289)
14. Mehilli J, Pache J, bdel-Wahab M, et al. Drug-eluting versus baremetal stents in saphenous vein graft lesions (ISAR-CABG): a randomised controlled superiority trial. Lancet 2011;378:1071-8.
15. Meier P, Brilakis ES, Corti R, et al. Drug-eluting versus bare-metal stent for treatment of saphenous vein grafts: a meta-analysis. PLoS One 2010;5:e11040.
16. Lagerqvist B, Carlsson J, Frobert O, et al. Stent thrombosis in Sweden: a report from the Swedish Coronary Angiography and Angioplasty Registry. Circ Cardiovasc Interv 2009;2:401-8.
17. James SK, Stenestrand U, Lindback J, et al. Long-term safety and efficacy of drug-eluting versus bare-metal stents in Sweden. N Engl J Med 2009;360:1933-45.
18. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983;70:41-55.
19. Frøbert O, Lagerqvist B, Carlsson J, et al. Differences in restenosis rate with different drug-eluting stents in patients with and without diabetes mellitus: a report from the SCAAR (Swedish Angiography and Angioplasty Registry). J Am Coll Cardiol 2009;53:1660-7.
20. Kirtane AJ, Gupta A, Iyengar S, et al. Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies. Circulation 2009;119:3198-206.
21. Lupi A, Navarese EP, Lazzero M, et al. Drug-eluting stents vs. bare metal stents in saphenous vein graft disease. Insights from a meta-analysis of 7,090 patients. Circ J 2011;75:280-9.
22. Paradis JM, Belisle P, Joseph L, et al. Drug-eluting or bare metal stents for the treatment of saphenous vein graft disease: a Bayesian meta-analysis. Circ Cardiovasc Interv 2010;3:565-76.
23. Hakeem A, Helmy T, Munsif S, et al. Safety and efficacy of drug eluting stents compared with bare metal stents for saphenous vein graft interventions: a comprehensive meta-analysis of randomized trials and observational studies comprising 7,994 patients. Catheter Cardiovasc Interv 2011;77:343-55.
24. Ekerstad N, Swahn E, Janzon M, et al. Frailty is independently associated with short-term outcomes for elderly patients with non-ST-segment elevation myocardial infarction. Circulation 2011;124:2397-404.
25. Shi Y, Patel S, Davenpeck KL, et al. Oxidative stress and lipid retention in vascular grafts: comparison between venous and arterial conduits. Circulation 2001;103:2408-13. (Pubitemid 32448808)
26. Okada SS, Golden MA, Raghunath PN, et al. Native atherosclerosis and vein graft arterialization: association with increased urokinase receptor expression in vitro and in vivo. Thromb Haemost 1998;80:140-7. (Pubitemid 28353512)
27. Claessen BE, Smits PC, Kereiakes DJ, et al. Impact of lesion length and vessel size on clinical outcomes after percutaneous coronary intervention with everolimus- versus paclitaxel-eluting stents pooled analysis from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice) randomized trials. JACC Cardiovasc Interv 2011;4:1209-15.
28. Ribichini F, Pugno F, Ferrero V, et al. Long-term histological and immunohistochemical findings in human venous aorto-coronary bypass grafts. Clin Sci (Lond) 2008;114:211-20. (Pubitemid 351293996)
29. Ko DT, Guo H, Wijeysundera HC, et al. Long-term safety and effectiveness of drug-eluting stents for the treatment of saphenous vein grafts disease: a population-based study. JACC Cardiovasc Interv 2011;4:965-73.